Sabbin bayanai daga binciken da ake yi na Phase 3 yana ƙara bayyana tasirin VUMERITY® (Dilosimil fumarate) da ingantaccen haƙuri na gastrointestinal.
Idan aka kwatanta da Ocrevus® (ocrelizumab), ainihin binciken ya kimanta ingancin fa'idodin rayuwa masu alaƙa da TYSABRI® (natalizumab)
Sauran bincike na rayuwa na ainihi sun ba da rahoton fa'idodin PLEGRIDY® (peginterferon beta-1a) da AVONEX® (interferon beta-1a) a cikin tsofaffi marasa lafiya tare da sclerosis da yawa.
Cambridge, Massachusetts, Satumba 11, 2020 (Labaran Duniya) -Biogen Inc. (NASDAQ: BIIB) a yau ta sanar da sabbin bayanai da ke nuna fa'idodin masana'anta da ke jagorantar Multi sclerosis (MS) Inganci da amincin haɗin warkewa.Za a gabatar da waɗannan bayanan yayin taron haɗin gwiwa na takwas na MSVirtual2020, Kwamitin Jiyya na Sclerosis na Amirka da yawa da Kwamitin Bincike na Turai Multiple Sclerosis Jiyya (ACTRIMS-ECTRIMS), wanda za a gudanar daga Satumba 11 zuwa 13, 2020.
"Babban jami'in kula da lafiya na Biogen Maha Radhakrishnan, MD, ya ce: "Biogen yana alfahari saboda mun himmatu wajen magance matsalolin gaggawa da na dogon lokaci da marasa lafiyar MS ke fuskanta.“Bayanan da muke bayarwa akan ACTRIMS-ECTRIMS suna nuna ingantaccen sakamako.Babban fayil ɗin samfurin mu na MS yana ci gaba da bauta wa marasa lafiya tare da sake dawowa MS, ko da a ina suke cikin tsarin jiyya, da ci gaba da bincike da haɓaka Zuba Jari a cikin haɓaka ƙwararrun ƴan takarar magunguna.”
Sabbin bayanan lokaci na 3 sun ƙara fayyace ingancin VUMERITY® (Dilosimide fumarate) da haƙurin GI da aka ba da rahoton haƙuri.Sabbin bayanai daga shirin VUMERITY Mataki na 3 na asibiti sun ƙara ayyana sabuwar maganin fumarate na Biogen Tasiri da aminci.Idan aka kwatanta da TECFIDERA® (dimethyl fumarate) (n = 251) da tallafi, sakamakon binciken na EVOLVE-MS-2 na mako biyar ya ƙarfafa haƙurin gastrointestinal (GI) na marasa lafiya da aka tantance dangane da maganin VUMERITY Mahimmancin asibiti na karɓa (n) = 253) yana inganta tasirinsa akan ingancin rayuwar marasa lafiya tare da maimaita MS.Mahalarta binciken da suka yi amfani da VUMERITY sun ce ba su da yuwuwar kamuwa da alamun ciwon ciki da ke kawo cikas ga ayyukan yau da kullun ko kuma suna da alaƙa da rashin aiki, kuma akwai ƙarancin magungunan da ake amfani da su don magance alamun ciki.
Binciken bincike na binciken EVOLVE-MS-1 mai gudana ya kimanta tasirin VUMERITY akan sauye-sauyen girma na kwakwalwa da sauran alamun asibiti a cikin mutanen da suka sake dawowa MS (n = 365) da aka bi da su har zuwa shekaru biyu.Nazarin daban-daban sun nuna cewa raguwar ƙarar kwakwalwa na iya kasancewa da alaƙa da rashin fahimta, nakasar jiki da rage ingancin rayuwa a cikin marasa lafiya na MS.1,2, bayanan EVOLVE-MS-1 ya nuna:
Adadin canjin ƙarar ƙwaƙwalwa na shekara-shekara na mahalarta binciken da suka karɓi maganin VUMERITY na tsawon shekaru biyu yayi kama da na mutane masu lafiya.tare da
Kusan kashi 90% na marasa lafiya da ke karɓar maganin VUMERITY ba su da tabbacin ci gaban nakasa, kuma kusan kashi 84% ba su sake dawowa cikin shekaru biyu ba.
Hakanan za'a gabatar da bayanan ƙarshe daga binciken 3 na ENDORSE a taron, wanda ke ƙara tabbatar da ci gaba da inganci da ingantaccen ingantaccen tsaro na TECFIDERA a cikin marasa lafiya har zuwa shekaru 13.
Bayanan na ainihi daga wani bincike daban na yawan yawan MS na yau da kullum ya nuna cewa ta hanyar MS PATHS (Fasaha na Ci gaban Fasaha da Lafiya), TYSABRI® (natalizumab), PLEGRIDY® (pegylated interferon beta-1a) da sakamakon AVONEX® (interferon beta-1a) sun inganta., Biogen yana haɗin gwiwa tare da manyan cibiyoyin MS a Turai da Amurka don samar da daidaitattun bayanai, bayanai masu inganci daga ainihin-duniya MS masu haƙuri.Zuwa yau, fiye da marasa lafiya 17,000 sun shiga cikin MS PATHS.Bayanan da aka samu daga jiyya a cikin yanayi na ainihi yana goyan bayan ingantaccen sakamakon da ke hade da TYSABRI, PLEGIDYY da AVONEX.Sakamakon bincike daban daga bayanan MS PATHS yana nuna:
A cikin kwatankwacin farko na tsarin MS PATHS daidaitaccen hoton maganadisu na maganadisu (MRI), sauye-sauye a lokacin tsawaita lokacin dosing (EID; n = 85) na natalizumab an kwatanta su da kwakwalwar MRI da aka yarda (ma'anar bin 0.8 shekaru).Sau ɗaya kowane mako huɗu (Q4W; n = 569).Binciken ya ba da rahoton wani bambance-bambance mai mahimmanci a cikin sabon cutar T2, masu canjin cutar T2 da ƙimar atrophy na kwakwalwa.Bambance-bambance a cikin na'urori na MRI da ka'idojin saye a cikin aikin asibiti suna yin kwatanta sakamakon MRI na kwakwalwa da kalubale.Yawancin bincike na ainihi na duniya sun nuna cewa ingancin natalizumab EID yayi kama da adadin Q4W da aka yarda.3-7Biogen ya ci gaba da kimanta tasiri, aminci da juriya na natalizumab EID ta hanyar gwajin NOVA mai zuwa (NCT03689972), kuma kwanan nan ya ƙaddamar da aikace-aikacen gudanarwa na subcutaneous ga hukumar gudanarwa.Idan an amince, Zai samar da ƙarin zaɓuɓɓuka don gudanar da TYSABRI.
Dangane da ƙimar Neuro-QoL (Ingantacciyar Rayuwa a cikin Cututtukan Jijiya), jiyya na TYSABRI yana da haɓaka mafi girma a wasu ingancin rayuwa fiye da Ocrevus® (ocrelizumab).A cikin nazarin rukuni na marasa lafiya da suka dace da TYSABRI ko Ocrevus, an lura cewa 9 daga cikin 12 Neuro-QoL domains a cikin marasa lafiya da aka yi da TYSABRI sun inganta sosai (n = 144).4 daga cikin yankuna 12 sun inganta sosai (n = 502)).Gabaɗaya, haɓakar haɓakar TYSABRI na shekara-shekara ya fi na Ocrevus, kuma ana lura da bambance-bambance masu mahimmanci ta fuskoki uku: tasiri mai kyau da jin daɗin rayuwa, gamsuwa da matsayin zamantakewa da ayyukan, da kuma rashin bacci.
Idan aka kwatanta da marasa lafiya na MS a ƙarƙashin shekaru 60 (n = 729), sakamakon asibiti na marasa lafiya na MS sama da shekaru 60 (n = 286) ya nuna cewa a cikin ƙungiyoyin shekaru biyu, duka PLEGRIDY da AVONEX na iya ba da fa'idodin warkewa.Bayanan sun nuna cewa gwajin saurin sarrafawa (PST) da gwajin ji da gani (CST) na kungiyoyin shekaru biyu sun inganta cikin fiye da shekara guda.Bugu da ƙari, yawancin mahalarta a cikin ƙungiyoyin shekaru biyu ba su sake komawa cikin shekaru biyu ba.
Bayanai daga nazarin mataki na 1 na BIIB091 yana goyan bayan ci gaba da jiyya na MSBiogen, kuma an bayar da bayanai daga nazarin mataki na 1 na BIIB091.BIIB091 zaɓi ne, mai jujjuyawa (ba mai haɗawa) ƙananan ƙwayoyin ƙwayoyin cuta na aikin baka na Bruton's tyrosine kinase (BTK) Agent.Bayanan sun kimanta aminci, haƙuri, pharmacokinetics da pharmacodynamics na guda ɗaya da haɓakar allurai na baka a cikin batutuwan manya masu lafiya.Zaɓin hanawar BTK na iya zama da amfani ga maganin MS ta hana kunna ƙwayoyin B da ƙwayoyin myeloid ba tare da raguwar ƙwayoyin rigakafi ba.
Gabatarwar bayanai akan ACTRIMS-ECTRIMS: Lura: Duk bayanan gabatarwa na MSVirtual2020 za su kasance akan layi da karfe 8 na safe agogon Gabas ranar Juma'a, 11 ga Satumba, 2020.
Idan aka kwatanta da dimethyl fumarate a cikin EVOLVE-MS-2, ingantaccen haƙuri na GI na Diroximel fumarate yana da alaƙa da mahimmancin asibiti na ingancin rayuwa (Poster 0214)
Tasirin Diroximel fumarate akan sauye-sauyen girma na kwakwalwa da ci gaban nakasa a cikin manya tare da EVOLVE-MS-1 relapsing-remitting multiple sclerosis (Poster P0205)
Tsaro da ingancin marasa lafiya da aka bi da su tare da dimethyl fumarate kuma ana bin su har tsawon shekaru 13: sakamakon ƙarshe na ENDORSE (dandamali FC02.05-Lahadi, Satumba 13th 1: 48-2: 00 US Eastern Time)
Sakamakon rediyo na marasa lafiya tare da tsawaita allurai na Natalizumab ba su bambanta da daidaitattun allurai na tazara a cikin MS PATHS (Poster P0360)
Tasirin Natalizumab akan Ingancin Rayuwa a cikin Ƙungiya ta Gaskiya na Marasa lafiya da yawa Sclerosis: Sakamakon Hanyar MS (Poster P1036)
Halaye da sakamakon asibiti na tsofaffi marasa lafiya na MS tare da Peginterferon Beta-1a ko intramuscular interferon Beta-1a a cikin maganin hanyar MS (Poster P0843)
Nazarin lokaci na 1 na BIIB091 (mai hana tyrosine kinase (BTK) mai hanawa na Bruton) a cikin mahalarta masu girma masu lafiya: Sakamakon farko (Poster P0186)
Game da VUMERITY® (Dilosemate Fumarate) VUMERITY fumarate ne na baka tare da tsarin sinadarai kwata-kwata daban-daban da TECFIDERA® (Dimethyl Fumarate), wanda aka amince da shi a Amurka don maganin sclerosis da yawa a cikin manya. cututtuka masu maimaitawa da kuma cututtuka masu ci gaba na sakandare masu aiki.Bayan shigar da jiki, VUMERITY yana saurin canzawa zuwa monomethyl fumarate, wannan metabolite mai aiki na dimethyl fumarate.
An hana VUMERITY a cikin marasa lafiya waɗanda ke fama da rashin lafiyar Diroximel fumarate, dimethyl fumarate ko duk wani abubuwan da ake amfani da su na VUMERITY;da marasa lafiya shan dimethyl fumarate.Mummunan illar VUMERITY sun dogara ne akan bayanan dimethyl fumarate (mai aiki iri ɗaya kamar VUMERITY), gami da halayen rashin lafiyan da angioedema, ci gaba da multifocal leukoencephalopathy, wanda ke da wuyar samun damar kwakwalwa Cutar Kwayar cuta tana da alaƙa da mutuwa ko rashin lafiya mai tsanani.Nakasa, raguwar matsakaicin adadin lymphocyte a cikin shekarar farko na jiyya, shingles da sauran cututtuka masu tsanani, lalacewar hanta da kuma zubar da ruwa.Mafi yawan abubuwan da ba su dace ba da aka samu ta amfani da bayanai daga dimethyl fumarate (tare da nau'in ƙwayar cuta mai aiki kamar VUMERITY) sun kasance masu ruwa, ciwon ciki, gudawa, da tashin zuciya.
Da fatan za a danna nan don mahimman bayanan aminci da cikakkun bayanan likitanci, gami da bayanan haƙuri don VUMERITY a Amurka.
Game da TECFIDERA® (dimethyl fumarate) TECFIDERA hanya ce ta jiyya don sake dawowa da cutar sclerosis (MS) a cikin manya.Ita ce maganin da aka fi rubutawa don sake dawowa MS a duniya.An tabbatar da rage yawan sake dawowa na MS kuma ya rage shi.Yana ci gaba zuwa nakasa kuma yana rinjayar adadin raunukan kwakwalwar MS, kuma yana tabbatar da cewa halayen lafiyar marasa lafiya da MS sun sake dawowa yana da kyau.An amince da TECFIDERA a cikin ƙasashe / yankuna na 69 kuma an kula da marasa lafiya 475,000, wanda ke nufin fiye da 950,000 marasa lafiya-shekarun marasa lafiya suna amfani da kuma rubuta TECFIDERA.Daga cikin waɗannan, marasa lafiya 6,335 (shekarun masu haƙuri 14,241) sun fito ne daga gwaji na asibiti8.
An hana TECFIDERA a cikin marasa lafiya waɗanda ke da rashin lafiyar dimethyl fumarate ko duk wani abu na TECFIDERA.Mummunan sakamako masu illa sun haɗa da halayen rashin lafiyar jiki da angioedema, da kuma lokuta na ci gaba da multifocal leukoencephalopathy (mafi yawan kamuwa da cututtuka na ƙwayar cuta na kwakwalwa da ke hade da mutuwa ko rashin lafiya mai tsanani) an lura da su a cikin marasa lafiya na TECFIDERA tare da lymphopenia na dogon lokaci, kodayake rawar da lymphopenia ba shi da tabbas a cikin waɗannan lokuta. .Sauran munanan illolin sun haɗa da raguwar matsakaicin ƙididdiga na lymphocyte a cikin shekarar farko ta jiyya, shingles da sauran cututtuka masu tsanani, lalacewar hanta da kuma zubar da ruwa.A cikin gwaje-gwajen asibiti, abubuwan da suka fi dacewa da abubuwan da suka shafi TECFIDERA sun hada da ruwa, ciwon ciki, gudawa da tashin zuciya.
Da fatan za a danna nan don mahimman bayanan aminci da cikakkun bayanan likitanci, gami da bayanin haƙuri na TECFIDERA a Amurka, ko ziyarci gidan yanar gizon samfur a ƙasarku/yankinku.
Game da TYSABRI® (natalizumab) TYSABRI magani ne mai mahimmanci don sake dawowa da cutar sclerosis (RMS), wanda za'a iya amfani dashi don sake dawowa MS a cikin manya.Gwaje-gwaje na asibiti sun tabbatar da cewa wannan magani zai iya rage ci gaban nakasa ta jiki kuma ya rage samuwar sababbin raunuka na kwakwalwa da kuma rage sake dawowa.An amince da TYSABRI a cikin ƙasashe/yankuna 80.Dangane da gwaje-gwajen asibiti da bayanan likitanci, TYSABRI ta karɓi maganin TYSABRI don fiye da mutane 213,000 a duk duniya, tare da fiye da shekaru 835,000 na haƙuri.9
TYSABRI yana ƙara haɗarin ci gaba na leukoencephalopathy multifocal (PML), kamuwa da cuta mai saurin kamuwa da cuta na kwakwalwa wanda ke da alaƙa da mutuwa ko nakasa mai tsanani.Halin haɗarin da ke ƙara haɗarin PML shine kasancewar ƙwayoyin rigakafi na anti-JC, yin amfani da magungunan rigakafi da TYSABRI don dogon magani.Marasa lafiya da waɗannan abubuwan haɗari guda uku suna da haɗarin PML mafi girma.Lokacin farawa da ci gaba da jiyya tare da TYSABRI, likitoci yakamata suyi la'akari ko fa'idodin da ake tsammani na TYSABRI ya isa ya kashe wannan haɗarin.
Hakanan TYSABRI yana ƙara haɗarin kamuwa da cutar encephalitis da sankarau da ke haifar da cutar ta herpes simplex da ƙwayoyin cuta varicella-zoster.A cewar rahotanni, marasa lafiya na MS da ke karɓar TYSABRI suna da mummunan hali, masu barazana ga rayuwa har ma da mutuwa bayan kasuwa.A cikin yanayin bayan tallace-tallace, akwai kuma lalacewar hanta mai mahimmanci na asibiti, gami da gazawar hanta mai tsanani wanda ke buƙatar dasawa.Sauran munanan abubuwan da suka faru a cikin marasa lafiya da aka bi da su tare da TYSABRI sun haɗa da halayen rashin hankali (kamar rashin lafiyar jiki) da cututtuka, ciki har da cututtuka masu dacewa da sauran cututtuka masu haɗari.
Da fatan za a danna nan don mahimman bayanan aminci, gami da faɗakarwar akwati, da cikakkun bayanan likitanci, gami da jagorar magunguna na TYSABRI na Amurka, ko ziyarci gidan yanar gizon samfurin a ƙasarku/yankinku.
Game da PLEGRIDY® (pegylated interferon β-1a) PLEGRIDY pegylated interferon ne na subcutaneous, sau ɗaya kowane mako biyu, don maimaita nau'in sclerosis (MS) a cikin manya, wanda shine mafi yawan nau'in MS.Tsarin gama gari.A halin yanzu an amince da PLEGRIDY a cikin fiye da ƙasashe / yankuna 60, gami da Amurka, Kanada, Ostiraliya da Switzerland, da Tarayyar Turai gabaɗaya.Dangane da bayanan likitanci, kusan mutane 57,000 a duk duniya sun sami magani PLEGRIDY, tare da fiye da shekaru 107,000 na haƙuri.10Biogen ya ci gaba da aiki don samar da PLEGRIDY a wasu ƙasashe / yankuna a duniya.
Inganci da amincin PLEGRIDY suna samun goyan bayan ɗaya daga cikin manyan binciken bincike, wanda yayi amfani da maganin interferon a cikin marasa lafiya tare da sake dawowa-remitting MS.A cikin nazarin asibiti, an tabbatar da cewa PLEGRIDY na iya rage yawan sake dawowa na MS, rage jinkirin ci gaban nakasa da kuma rage yawan raunin kwakwalwa a cikin MS.A lokaci guda, an tabbatar da cewa amincin marasa lafiya da MS sun sake dawowa yana da kyau.Abubuwan da aka ba da rahoto sun haɗa da matsalolin hanta, ciki har da gazawar hanta da haɓakar enzymes hanta;bakin ciki ko tunanin kashe kansa;mummunan rashin lafiyan halayen;matsalolin zuciya, gami da gazawar zuciya;cututtuka na autoimmune;rage yawan adadin farin jini ko platelet;da kamewa.A cikin gwaje-gwajen asibiti, mafi yawan al'amuran da suka fi dacewa da su tare da PLEGRIDY sune halayen wurin allura da alamun mura.Ana iya samun jerin abubuwan da ba su da kyau a cikin cikakkiyar alamar samfurin PLEGRIDY na kowace ƙasa da aka sani.
Da fatan za a danna nan don mahimman bayanan aminci da cikakkun bayanan rubutawa, gami da jagororin jiyya na PLEGRIDY na Amurka, ko ziyarci gidan yanar gizon samfurin a cikin ƙasarku/yankinku.
Game da AVONEX® (Interferon beta-1a) An tsara AVONEX don sake dawowa MS, kuma an amince da shi a cikin ƙasashe sama da 90.Dangane da bayanan likitanci, fiye da mutane 580,000 a duk duniya sun sami magani na AVONEX, tare da fiye da shekaru 2.6 na haƙuri na haƙuri.11AVONEX an tsara shi don maganin sake dawowa mahara sclerosis (MS), ciki har da cututtukan da aka keɓance na asibiti, sake dawowa- manya tare da ƙananan cuta da cututtukan ci gaba na sakandare mai aiki.
A cewar rahotanni, marasa lafiya da ke karɓar AVONEX suna da alamun rashin tausayi, tunanin suicidal ko psychosis, kuma yawan lokuta na kashe kansa ya karu.Ƙananan marasa lafiya suna ba da rahoton mummunar lalacewar hanta, ciki har da gazawar hanta.An ba da rahoton lokuta marasa ƙarancin rashin lafiyan.Ko da yake beta interferon ba shi da wani guba na zuciya kai tsaye, an ba da rahoton cewa babu majiyyata da aka sani da cutar da ta haifar da gazawar zuciya, cardiomyopathy, da cardiomyopathy na gazawar zuciya.Kwarewar tallace-tallace bayan tallace-tallace ya nuna cewa an rage adadin ƙwayoyin jini na gefe.A cewar rahotanni, marasa lafiya da ke amfani da AVONEX suna da rikice-rikice, ciki har da wadanda ba su da tarihin kama.An ba da rahoton cututtukan autoimmune na gabobin da aka yi niyya da yawa.Ana ba da shawarar yin gwajin jini na yau da kullun, ilimin jini, aikin hanta da gwajin aikin thyroid akai-akai.
Da fatan za a danna nan don mahimman bayanan aminci da cikakkun bayanan rubutawa, gami da jagororin jiyya na AVONEX a Amurka, ko ziyarci gidan yanar gizon samfurin a ƙasarku/yankinku.
Game da Biogen At Biogen, manufarmu a bayyane take: mu majagaba ne a fagen ilimin jijiya.Biogen yana ganowa, haɓakawa da samar da sabbin hanyoyin warkewa a duniya don mutanen da ke fama da matsanancin cututtukan jijiya da cututtukan neurodegenerative da jiyya masu alaƙa.Biogen daya ne daga cikin kamfanonin fasahar kere-kere na farko na duniya, wanda Charles Weissmann, da Heinz Schaller, da Kenneth Murray, da wadanda suka lashe kyautar Nobel suka kafa a shekarar 1978, Walter Gilbert da Phillip Sharp.A yau, Biogen yana da babban fayil ɗin magani don maganin sclerosis da yawa, ƙaddamar da farkon yarda da maganin atrophy na tsoka na kashin baya, kasuwancin biosimilars na ci-gaban ilimin halitta, kuma ya mai da hankali kan haɓaka sclerosis da yawa da neuroimmunology.Cutar cutar Alzheimer da lalata, cututtukan neuromuscular, rikicewar motsi, ilimin ido, immunology, cututtukan neurocognitive, m neuropathy da zafi.
Za mu buga bayanai akai-akai waɗanda zasu iya zama masu mahimmanci ga masu saka hannun jari akan gidan yanar gizon mu www.biogen.com.Don ƙarin koyo, da fatan za a ziyarci www.biogen.com kuma ku biyo mu akan kafofin watsa labarun Twitter, LinkedIn, Facebook, YouTube.
Harbour Safe Harbor Biogen Wannan sanarwar manema labarai ta ƙunshi maganganun sa ido, gami da bayanai game da yuwuwar fa'idodi, aminci da tasiri na VUMERITY, TECFIDERA, TYSABRI, PLEGIIDY da BIIB091 a ƙarƙashin tanadin tashar jiragen ruwa mai aminci na Dokar Sake Gyaran Shari'a ta Masu zaman kansu na 1995;Sakamakon wasu ainihin bayanai;Nazarin EVOLVE-MS-2, nazarin ENDORSE Mataki na 3 da sakamakon binciken BIIB091 Phase 1;MS ganewa da magani;shirin mu na ci gaban jiyya na MS;yuwuwar tattaunawa ta tsari, ƙaddamarwa da yarda da Shirye-shiryen lokaci;yuwuwar kasuwancin kasuwancin Biogen, gami da VUMERITY, TECFIDERA, TYSABRI, PLEGRIDY da BIIB091;da kuma kasada da rashin tabbas da ke tattare da haɓaka magunguna da kasuwanci.Waɗannan kalamai masu sa ido na iya amfani da kalmomi kamar "manufa", "tsammata", "gaskanta", "iya", "kimantawa", " tsammanin", "hasa", "manufa", "nufin", "mai iya" zuwa gane."," "tsari", "maiyuwa", "mai yiwuwa", "yi", "yi" da sauran kalmomi da kalmomi masu ma'ana iri ɗaya.Ci gaban miyagun ƙwayoyi da tallace-tallace sun haɗa da babban haɗari, kuma ƙananan ƙananan bincike da tsare-tsaren ci gaba suna haifar da tallace-tallace na samfurori Sakamakon gwaje-gwaje na farko na asibiti bazai wakiltar cikakken sakamako ba ko sakamakon sakamakon gwaji na asibiti ko babba, kuma ba zai iya ba. suna tabbatar da amincewar tsari.Kada ku dogara da yawa akan waɗannan maganganun ko bayanan kimiyya da aka bayar.
Waɗannan maganganun sun haɗa da haɗari da rashin tabbas, kuma suna iya haifar da sakamako na ainihi ya bambanta da zahiri da sakamakon da aka nuna a cikin irin waɗannan maganganun, gami da amma ba'a iyakance ga faruwar munanan al'amuran tsaro da/ko abubuwan da ba zato ba tsammani waɗanda wasu bayanai ko bincike suka haifar;kudaden da ba zato ba ko jinkirta Hatsari;Damuwar da ba zato ba tsammani na iya tasowa saboda wasu bayanai, bincike ko sakamako yayin gwaji na asibiti;Rashin iya karewa da aiwatar da bayanan mu, haƙƙin mallaka na ilimi da sauran mallaka, da rashin tabbas da ke da alaƙa da iƙirarin mallakar fasaha da ƙalubale;Hukumomin gudanarwa na iya buƙatar ƙarin bayani ko ƙarin bincike, ko ƙila ba za su iya amincewa ko ƙila su jinkirta amincewar ƴan takarar mu na muggan ƙwayoyi ko faɗaɗa alamar samfur ba;rashin samun amincewar doka a wasu hukunce-hukuncen;da'awar abin alhaki na samfur;haɗarin haɗin gwiwar ɓangare na uku;kuma Cutar ta COVID-19 da ke gudana tana da tasirin kai tsaye da kai tsaye akan kasuwancinmu, sakamakon aiki da yanayin kuɗi.Da yawa amma ba duka abubuwan da aka jera a sama ba na iya haifar da sakamako na gaske ya bambanta da tsammaninmu a cikin kowane maganganun sa ido.Ya kamata masu saka hannun jari suyi la'akari da wannan sanarwa na gargaɗin da abubuwan haɗari da muka gano a cikin rahotonmu na baya-bayan nan na shekara-shekara ko na kwata da sauran rahotannin da muka shigar da Hukumar Tsaro da Musanya.Waɗannan maganganun sun dogara ne akan imaninmu da tsammaninmu na yanzu kuma suna wakiltar yanayin ne kawai tun daga ranar da aka fitar da wannan labarin.Ko saboda sabbin bayanai, abubuwan da ke faruwa a nan gaba ko wasu dalilai, ba mu dau nauyin sabunta duk wata sanarwa ta gaba a bainar jama'a.
Mowry EM, Beheshtian A, Waubant E, da dai sauransu. Ingancin rayuwa a cikin sclerosis da yawa yana da alaƙa da nauyin cuta da ma'aunin ma'aunin ƙwaƙwalwa.Neurology.2009;72 (20): 1760-1765.
Lanz M, Hahn HK, Hildebrandt H. Brain atrophy da rashin fahimta a cikin sclerosis da yawa: bita [An buga gyare-gyaren da aka buga a J Neurol.2008 Fabrairu;255 (2): 309-10.Jaridar Neurology.2007;254 Kari 2: II43-II48.
Foley J, Xiong K, Hoyt T, da dai sauransu. An canza matsakaicin matakin ƙwayar neurofilament a cikin marasa lafiya tare da relapsing-remitting multiple sclerosis daga natalizumab sau ɗaya kowane mako 4 zuwa tsawaita gudanarwar tazara.AAN 2020;S10.009.
Butzkueven, Kappos L, Spelman T.ECTRIMS 2019;P1033.
Yamout B, Sahraian MA, Ayoubi NE, da sauransu. Inganci da amincin natalizumab ana gudanar da shi a tsawan lokaci.Rikicin Dangantakar Mult Scler.2018;24: 113-116.
Zhovtis Ryerson L, Frohman TC, Foley J, da dai sauransu. Extended tazara gudanarwa na natalizumab a mahara sclerosis.J Neurol Neurosurgery Psychiatry.2016; 87: 885-889.
Bomprezzi R, PawateS.Extended tazara dosing na natalizumab: 7 shekaru gwaninta a cikin biyu cibiyoyin.Ciwon Adv Neurol.2014;7: 227-231.
Tun daga Yuni 30, 2020, dangane da haɗin bayanan tallace-tallace daga gwaje-gwajen asibiti na takardar sayan magani da fallasa zuwa TECFIDERA.
Tun daga Yuli 31, 2020, haɗe bayanan tallace-tallace dangane da takaddun magani da gwajin asibiti na bayyanar TYSABRI.
(Bloomberg) - Farashin hannun jari na SAP SE ya fadi da kusan 21%, raguwar kwana guda mafi girma tun 1999. A baya can, kamfanin na Walldorf ya rage hasashen kudaden shiga na cikakken shekara kuma ya ce yana sa ran sabon zagaye na kudaden shiga.An kulle shi zuwa rabin farko na 2021, buƙata ta lalace.A cikin gwajin Christian Klein, ya zama babban Shugaba a cikin Afrilu.Barkewar cutar za ta jinkirta kudaden shigar gajimare na SAP, gaba daya tallace-tallace da kuma manufofin ribar aiki na shekara guda ko biyu, musamman kamar yadda kamfanin software ya fada a cikin wata sanarwa ranar Lahadi.SAP ta ce tana sa ran ci gaba mai iyaka da ribar riba a cikin shekaru biyu masu zuwa, kuma za ta motsa shirinta na dabarun 2023 zuwa 2025. Klein ya fada a cikin kiran taron a ranar Litinin cewa yana tsammanin SAP ya fada a cikin wata sanarwa cewa hangen nesa na baya "yana ɗauka. cewa tattalin arzikin kasar zai sake budewa, kuma za a samu saukin kulle-kullen jama’a, wanda hakan zai haifar da ci gaba a sannu a hankali a yanayin bukatu a kashi na uku da na hudu.”Kwanan nan kamfanin ya yi hasashen cewa nan da shekarar 2020, bisa kayyade farashin canji, kudaden da aka daidaita za su kai Yuro biliyan 27.2 zuwa Yuro biliyan 27.8 (dala biliyan 32.2 zuwa dalar Amurka biliyan 32.9), wanda ya yi kasa fiye da yadda ake tsammani kuma ya karu zuwa Yuro biliyan 28.5 daga jagorar da ta gabata. ya kai 27.8 Yuro.YuroSAP ta kuma bayyana cewa kasuwancinta na Concur ba zai ci gajiyar kudaden shiga da suka shafi tafiye-tafiye a wannan shekara ba.Masanin OddoBHF Nicholas David ya rubuta a cikin wani rahoto cewa yana da wuya a sami wasu sakamako masu kyau daga sakamakon Labarai.Tsammanin kasuwa don buri na tsakiyar wa'adi yana da / tsoratarwa, amma sabon buri ya yi ƙasa da mafi ƙarancin tsammanin."Qualtrics IPOSAP ya ce sashin software na Qualtrics yana cikin ci gaba na jeri.A watan Yuli ta sanar da cewa ta yanke shawarar siyan kamfanin a farashi mai daraja kuma ya fito fili a Amurka cikin kasa da shekaru biyu.Wannan juyi ne da ba zato ba tsammani kuma ya nuna sauyi na dabara ƙarƙashin jagorancin Klein.Babban jami'in kudi Luka Mucic ya fada ta wayar tarho ranar Litinin cewa "Mun sami ci gaba sosai a shirye-shiryen IPO na Qualtrics."Karfin aikin Qualtrics na kwata-kwata zai kafa tushe don ci gaba a shekara mai zuwa."Sabon hasashen da aka daidaita kudaden shigar girgije ana sa ran zai karu daga Yuro biliyan 8 zuwa Yuro biliyan 8.2 a shekarar 2020, kasa da kiyasin da aka yi a baya na Yuro biliyan 8.3 zuwa Yuro biliyan 8.7.Ribar aiki na Yuro a bana zai kasance tsakanin Yuro biliyan 8.1 zuwa Yuro biliyan 8.5, wanda ya yi kasa da yadda ake sa ran samun Euro biliyan 8.7.SAP ta fadada burinta na tsakiyar wa'adin zuwa sama da Euro biliyan 36 a cikin jimlar kudaden shiga ta 2025 kuma za ta kai Euro biliyan 35 nan da 2023.Ribar da ba ta IFRS ba a cikin rubu'i na uku na aiki a cikin kwata na uku ya faɗi 12% kowace shekara zuwa Yuro biliyan 2.07.Idan aka kwatanta da Yuro biliyan 2.15 da manazarta suka yi nazari da Bloomberg, kudaden shiga a lokacin ya ragu da kashi 4% zuwa Yuro biliyan 6.54, yayin da matsakaicin hasashen manazarta ya kai Yuro biliyan 6.89., Shugaban SAP ta hanyar PandemicU.K.CMA ta zana hanyarta kuma ta fara bincike na antitrust akan Sinch, an ba da sashin SAP DealSAP zuwa JP Morgan Stanley, kuma JP Morgan yana gudanar da Qualtrics IPO (sabuntawa, wasu yanayi).Da fatan za a ziyarci Bloomberg.com don ziyarce mu kuma ku yi rajista a yanzu.Ci gaba da kasancewa jagora a matsayin mafi amintaccen tushen labaran kasuwanci.©2020 Bloomberg LP
Wani akawu na San Francisco ya tattauna mahimmancin gwamnatin Biden ga saka hannun jari a kowace tattaunawa da abokan ciniki.
Masu amfani waɗanda ba su ba da oda akan kowane dandamali na JD ba na iya karɓar rangwamen kuɗi!Tare da katin Visa ɗin ku, danna don biya a JD.com a karon farko kuma ku more ragi!
Wanda ya lashe kyautar Nobel a fannin tattalin arziki, farfesa a jami'ar Yale, Robert Shiller ya bukaci masu zuba jari da su yi taka tsantsan game da kasuwar hada-hadar hannayen jari a wani shafi na baya-bayan nan a jaridar New York Times.
Kamfanin ya ce Lee Kun-hee, wanda ya gina Samsung Electronics a matsayin wani katafaren kamfanin wayar salula na zamani da na’urar daukar hoto da talabijin, ya mutu ne a ranar Lahadin da ta gabata bayan da ya shafe fiye da shekaru shida yana kwance a asibiti sakamakon bugun zuciya a ranar Lahadi.Lee yana da shekaru 78 a wannan shekara.Ya haɓaka kamfanin Samsung ya zama kamfani mafi girma a Koriya ta Kudu kuma ya zama mafi arziki a Koriya ta Kudu.Jeong Sun-, Shugaba na kamfanin bincike na kamfanin Chaebul.com, ya ce: “Hasuwar Lee na ban mamaki a Koriya da yadda Koriya ta Kudu ke hadewa da dunkulewar duniya alama ce ta yadda Koriya da yawa za su tuna da mutuwarsa.
Shekaru hudu bayan rugujewar hukumar ta BHS, shin masana'antar tantancewa da aka zarga da kasa gano wata matsala ta canza?
A cewar rahotanni na CNBC, Jack Ma, wanda ya kafa Alibaba Group Holdings Limited (NYSE: BABA), ya fada a ranar Asabar cewa kyautar farko ta jama'a ta Ant Group (IPOs) a Shanghai da Hong Kong za ta zama kamfani mafi girma a duniya.Abin da ya faru: CNBC ya ce farashin IPO ya kasance daren Juma'a, amma Jack Ma bai bayyana takamaiman lambar ba, wanda za a sanar a mako mai zuwa.Tarihin ɗan adam-an ƙayyade a wajen birnin New York.Ma Yun ta ce a gun taron koli na Shanghai Bund.Attajirin na kasar Sin ya kira batun "abin al'ajabi."Ya ce: “Ba mu kuskura mu yi tunani a kai ba shekaru biyar ko uku da suka shige.“Ma Yun ta kuma yi kira da a yi gyare-gyare a harkokin banki da samar da wani sabon tsarin hada-hadar kudi na duniya baki daya.Dalilin da ya sa yake da mahimmanci: Bayar da tallafin jama'a na farko na kamfanoni masu goyon bayan Alibaba na iya samar da kusan kusan biliyan ɗaya na kudaden shiga, wanda zai sa ya zama Saudi Aramco Kyauta mafi girma na farko a duniya na dalar Amurka biliyan 29.4.Hannun jarin Aramco da aka fitar a watan Disamba 2019 ya doke Alibaba kuma ya lashe kambi na IPO mafi girma.Rahoton kudi na baya-bayan nan game da kudin shiga na Singapore's Sovereign wealth Fund GIC Private Limited na iya kasancewa a cikin wannan jerin.Zuba jarin ya zarce dalar Amurka biliyan 1.A cewar Reuters, Temasek na Singapore, mai saka hannun jari na Ant, shi ma ya nuna sha'awar hannun jari.Farashin farashi: Farashin hannun jari na Alibaba ya rufe kusan 1.2% ranar Juma'a zuwa dalar Amurka 309.92.Ya tashi da 0.11% yayin zaman ciniki na bayan sa'o'i.Ƙarin yarjejeniyoyin daga Ben Singa * Danna nan don duba zaɓin cinikin Ben Singa * Quibi ya rushe-wannan ra'ayin bai da ƙarfi, in ji Benzinga.com shugabancin (C) a cikin 2020: "Ko"Lokaci" ya ɓace.Benzinga baya bayar da shawarar zuba jari.duk haƙƙin mallaka.
Ba da gudummawa nan da nan don tallafawa hukumar kula da 'yan gudun hijira ta Majalisar Dinkin Duniya, domin 'yan gudun hijira su sami na'urorin gaggawa don magance damina da kuma ceto su daga bala'i!
Yana da sauƙi don siyan hannun jari, amma yana da wuya a siyan hannun jari masu dacewa ba tare da dabarun gwajin lokaci ba.Don haka, menene mafi kyawun hannun jari don siye ko saka akan jerin agogo yanzu?
Gaba ya fadi da karfi.Kasuwar hannun jari na iya tafiya tare da shugabanni kamar Microsoft da Tesla.Yayin da zabe ke gabatowa kuma cutar coronavirus ta yi yawa, wannan shine mako mafi girma na samun kudin shiga.
Harry Markopolos (Harry Markopolos), tsohon ƙwararren ƙwararru wanda ya juya zuwa mai binciken zamba na kuɗi mai zaman kansa, ya gano tsarin dala biliyan 65 Bernie Madoff Ponzi, amma SEC ta yi watsi da shi tsawon shekaru tara.A matsayinsa na mai sukar lamirin hukumomin Amurka, Harry yanzu yana kallon fagen tantancewa da kuma masana'antar inshora a matsayin babban shari'ar zamba ta gaba da za a bayyana.
Sabuwar shekara ta Hang Seng ta kan layi wanda za a cire haraji yana ba da ƙarin shekaru 10 na ƙarin tsayayyen kudin shiga kuma yana ba da garantin 1.73% -2% na sake saitin shiga shiga na ciki.Yana ɗaukar kusan mintuna 10 kawai don neman inshora akan layi kuma yi aiki nan da nan.
Wasu mutane uku da ke da masaniya kan lamarin sun ce babban mai hada wayar iPhone, Foxconn mazaunin Taiwan, ya kafa wata kungiya mai aiki da za ta bijirewa tasirin da kamfanin Luxshare na kasar Sin ke da shi.Kamfanin ya yi imanin cewa Luxshare ya zama rinjaye.barazana mai tsanani.Ɗaya daga cikin majiyoyin ta ce, wanda ya kafa Foxconn Guo Taiming ne ya fara aikin kuma wanda ake sa ran shine Luxshare <002475.SZ> mai hedikwata a Dongguan.Kamfanin ba a san shi sosai a duniya ba, amma ana sa ran zai zama kamfani na farko da zai taru a babban yankin kasar Sin.Hedikwatar iPhone - har yanzu, masana'antun Taiwan sun mamaye turf har yanzu.Majiyar ta ce, an kafa kungiyar aiki a shekarar da ta gabata, kuma tana gudanar da bincike kan fasahar Luxshare, da tsare-tsare na fadada aikin, dabarun daukar ma'aikata da kuma ko kamfanin (a halin yanzu yana da kashi 5% na kudaden shiga na Foxconn) yana samun goyon bayan kowace hukuma ta kasar Sin.
Za a fitar da rahoton babban abin da aka samu da kuma bayanan tattalin arziki na wannan makon nan gaba a cikin wannan makon, kuma yawancin hannayen jarin FAANG ana samun rahoton bayan rufewar ranar Alhamis.
AMD (AMD) na uku-kwata na samun rahoton da aka shirya za a fito da bayan rufe ranar Talata, wanda shi ne lokaci mai ban sha'awa ga semiconductor masana'antu.Jaridar Wall Street Journal ta ruwaito cewa AMD (AMD) na shirin fadada kasuwancin ta ta hanyar yuwuwar saye (XLNX) (XLNX).A lokaci guda, babban mai fafatawa a gasar (INTC) yana aiki tuƙuru don ci gaba da samar da ingantattun fasahar kere kere da ake buƙata don kera na'urori masu inganci.
Yi siyayya a manyan shagunan kan layi kuma ku kashe tare da katin Visa don jin daɗin kashe kusan 20%!Gano sabbin tarin Luisa Via Roma da Taylor yanzu!
Wani manazarci CFRA Garrett Nelson ya fada a wata hira da ya yi da Yahoo Finance ranar Juma’a cewa idan Joe Biden (Joe Biden) ya lashe zaben shugaban kasa, Tesla (NASDAQ: TSLA) ne zai zama babban wanda ya yi nasara.Abin da ya faru: Nielsen ya ce Tesla zai kasance "daya daga cikin manyan kamfanoni" masu nasara saboda kamfanin "motar lantarki ce mai tsabta."Manazarcin ya yi nuni da cewa gwamnatin Biden za ta ba da tallafi mai tsoka ga motocin lantarki.Manazarta na CFRA sun yi nuni da cewa Biden ya ba da shawarar "babban sikelin fadada kudaden harajin motocin lantarki" da "babban gina tashoshin cajin motocin lantarki."Nielsen ya ce: "Kuna tunanin ƙara yawan tashoshin cajin motocin lantarki da kusan sau 20.Zai taimaka kwarai da gaske wajen yada motocin lantarki."Mahimmanci: A yayin muhawarar shugaban kasa na karshe a Tennessee a makon da ya gabata, Biden ya ce gwamnatinsa za ta saka hannun jarin tashoshin cajin motocin lantarki 50,000 a kan babbar hanya.'Yan takarar sun ce wadannan tashoshin caji za su kai Amurka ga samun "makoma."Tsohon mataimakin shugaban kasar ya yi imanin cewa ra'ayinsa game da motocin lantarki zai iya magance sauyin yanayi kuma ya haifar da "sabbin ayyuka masu biyan kuɗi."Kamfanin da Elon Musk ke jagoranta ya sanar da rubu'in na uku a makon da ya gabata Kudaden shiga ya kai dalar Amurka biliyan 8.77, karuwar kashi 39% a shekara;Farashin farashi: Hannun hannun jari na Tesla sun rufe kusan kusan 1.2% ranar Juma'a zuwa $ 420.63.Idan Joe Biden ya ci nasarar TSLA DateFirmActionDaga na baya-bayan nan a cikin zaben Oktoba 2020 Ratings Morgan Stanley yana kiyaye ma'auni daidai (Oktoba 2020) Canaccord Genuity yana kula da cinikin da aka gudanar a watan Oktoba 2020 kuma ba tare da tsangwama ba ya fi kasuwa mafi girma.Dubi ƙarin kimar masu sharhi na TSLA.Dubi sabon kima na manazarta* Sabon bincike na Benza na ma'amala* Rives Musk ya ce za a samu sabis na haya na wata-wata a shekara mai zuwa.Jim Kramer ya ce Jim Tesla "Hauka ne" a cikin 2020 (C) Benzinga.com, wanda "ba daidai ba" Benzinga baya bayar da shawarar zuba jari.An kiyaye duk haƙƙoƙi.
Wace dabarar saka hannun jari ce ta tsaya tsayin daka?Zuba jarin girma.Masanan Wall Street sun yi imanin cewa hannun jari tare da haɓakar haɓakar haɓakar haɓakar haɓakar haɓakar haɓakar ƙima suna nuna wasu manyan hannun jari masu tursasawa.Wannan yuwuwar haɓakar ya wuce kewayon nan take, kuma waɗannan sunaye za su sami sakamako mai yawa a cikin 2020 da bayan haka.Wannan ya ce, a ce mafi ƙanƙanta, gano hannun jari da suka fada cikin wannan rukuni na iya zama kalubale.Manazarta sun yi imanin cewa dabara daya ita ce ta koma baya, duba babban hoto, da kuma mai da hankali kan kamfanonin da ke da ci gaba na dogon lokaci bisa nasarori masu ban sha'awa daga shekara zuwa yau.Tsayar da wannan a zuciya, mun yi amfani da bayanan TipRanks don gano hajoji na haɓaka uku waɗanda manazarta suka ƙima sosai.Dukkan hannayen jari guda uku sun sami ci gaba mai yawa a cikin 2020 kuma suna shirye don ci gaba da hawa.Kamfanin Wasan Kwallon Kafa na Pennsylvania (PENN) Da farko, muna da Kamfanin Wasan Kwallon Kafa na Ƙasar Pennsylvania, wanda ke da kuma sarrafa wuraren wasan kwaikwayo da na tsere da kasuwancin ƙarshen wasan bidiyo a Amurka.Sunan ya karu da kashi 146% na shekara zuwa yau, amma wasu manazarta Wall Street sun yi imanin cewa har yanzu akwai mai da yawa a cikin tankin.Kwanan nan PENN ta sanar da sakamakon kwata na uku a gaba, wanda ya zarce yadda ake tsammani.Kamfanin yana tsammanin ribar riba na kwata ya karu da fiye da maki 900, kuma EBITDAR da aka daidaita zai girma da kashi 5% a shekara, koda kuwa kudaden shiga ya ragu da kashi 10% a shekara.Masanin tauraro biyar Joseph Greff ya gaya wa abokan ciniki cewa "JP Morgan Chase" ya ce: "Murmurewa masana'antar caca ta yanki a watan Mayu / Yuni ya ci gaba har zuwa kwata na uku, kuma kudaden shiga ya fi yadda ake tsammani.Da zarar an danne bukatar Bayan dawowar al'ada, kuma tun da ingancin COVID na baya ya inganta, da kyar ake kashe kuɗin aiki.A baya mun zaci cewa an samu raguwar karuwar ci gaban.”Bayan ya faɗi hakan, Greif ya yarda cewa idan aka ba da fifikon farashin hannun jari, wasu manazarta sun bar relegation a baya. "Duk da haka, har yanzu ya yi imanin cewa "darajar da abin da zai haifar da gaba".Masu sharhi sun yi sharhi: “…Akwai yaƙi a cikin tunanin masu saka jari.Mun yi imanin wannan yana da lafiya ga hannun jari kuma yana da kusan wajibi don ci gaba da haɓaka;mun yi imanin cewa ba a ci zarafin masu saka hannun jari na wasan gargajiya gaba ɗaya ba.Mun yi imani da cewa masu zuba jari ne m game da PENN ta ikon yin gasa tare da DraftKings, Fanduel, Caesars Entertainment, MGM/GVC, da dai sauransu PENN ta zumunta ma'auni sheet size iya ciyar da saye halin kaka na farkon wasanni betting abokan ciniki, amma mun yi imani , Ganin cewa kwanan nan ãdalci. tara kudaden da aka tara dala miliyan 950, an rage hadarin wannan gasar a cikin wani yanayi mai ma'ana."Mafi mahimmanci, kwanan nan PENN ta ƙaddamar da ƙa'idar yin fare ta Barstool Sports a Pennsylvania.Greff ya kira wannan farkon sakin "mai ƙarfafawa dangane da duka girma da kuma kashe kuɗi," kuma ya tabbatar da "yiwuwar wata hanya ta musamman don samun rabo."Bugu da ƙari, ƙarfin Barstool Sportsbook yana ƙaruwa.Mafi mahimmanci, Greff ya yi imanin cewa wasan caca na yanzu da yanayin iGaming yayi kama da hauhawar kasuwannin yanki a cikin 1990s, lokacin da jihohin da ke da gibin kasafin kuɗi suka juya zuwa sabbin hanyoyin samun kuɗi, kamar wasannin kwale-kwale na ruwa don taimakawa rufe kasafin kuɗin su.kasawa.Dangane da haka, manazarcin ya ce: “Mun yi imanin cewa kowace jiha tana da kusan tsammanin irin na USSB da iGaming, kuma PENN za ta kasance daya daga cikin masu cin nasara.Muna son tsarin caca na tushen ƙasa / fare wasanni / iGaming a cikin Amurka kuma muna ganin ɗaki don haɓaka..”To, ba abin mamaki ba ne cewa Kabari ya zauna tare da Bijimai.Baya ga bayar da kima na "kiba", ya kuma saita farashin farashin $ 83 don hannun jari.Idan an cimma wannan burin a cikin watanni goma sha biyu masu zuwa, masu zuba jari na iya samun dawowar kashi 32%.(Don kallon rikodin waƙar Greif, danna nan.) Menene sauran Wall Street za su faɗi?An fitar da sayayya tara, hannun jari uku da sayarwa daya a cikin watanni ukun da suka gabata.Sakamakon haka, PENN ta sami “matsakaicin siyan” ƙimar yarjejeniya.Dangane da matsakaicin farashin dala $76.77, farashin hannun jari na iya tashi da kashi 22% a shekara mai zuwa.(Dubi nazarin hannun jari na Penn National Gaming akan TipRanks.) Redfin (RDFN) Redfin ya fara ne da taswira taswira kuma ya faɗaɗa kewayon samfurin sa don yin wasannin dangi, halartan taro da tafiyar da ayyukan cikin sauri da sauƙi.A kan titin Wall, wasu mutane suna tunanin cewa sunan ba wai kawai game da karuwar bukatar COVID ba ne, kuma ribar da ta samu na 113% na shekara zuwa yau shine farkon.Kodayake RDFN ta kawar da hasashen kashi na uku mai ƙarfi, masu saka hannun jari sun ɗan ji takaici da sakamakon.Jake Fuller na BTIG ya yi nuni da cewa farashin hannun jari na iya faduwa saboda “tsammani yana da yawa kuma matsakaicin karuwa a sikelin kudin shiga ya kai kusan kashi 2%” kuma “masu saka hannun jari na lokaci-lokaci suna ba da lada mai girma, yayin da RDFN a zahiri ke bayan wannan tsammanin.”Fuller ya yi imanin cewa RDFN ba shine abin da mutane da yawa ke mayar da hankali ba, wanda ke nuna cewa masu zuba jari ba su ga bayanin abin da aka samu ba.Duk da haka, yana tunanin Wall Street na iya rasa maɓalli na ɓangaren wuyar warwarewa.Manazarcin tauraro biyar ya ambata: "Abin da za a iya mantawa da shi a nan shi ne, RDFN ya kara yawan adadin hukumar ba tare da wani tasiri mai mahimmanci ga adadin canjin ba, wanda zai inganta hasashen ribar da RDFN ke samu."Don wannan karshen, zai sami babban riba na 2021 ana tsammanin ya karu da 47%.Duban cikakken bayani na kwata-kwata, RDFN ya sami buƙatu mai ƙarfi kuma kudaden shiga na sabis na ƙasa ya karu da kashi 36% duk shekara.Har ila yau, zirga-zirgar gidan yanar gizon da adadin ma'amala ya karu a wata-wata.Koyaya, ya kamata a lura cewa juzu'in yana haifar da kudaden shiga na kowace ma'amala.Fuller ya ce: "Wannan yana da mahimmanci saboda yana nuna cewa adadin hukumar da ake sa ran zai ba da gudummawa."“Bisa ga kididdigar mu, kudaden shiga na ayyukan gidaje daga 1.68% na GTV a cikin kwata na uku na 2019 da kwata na biyu na 2020 1.78% ya karu zuwa kimanin 1.85% a cikin kwata na uku na 2020. Babban babban riba mai maki hudu ya nuna. yawan zirga-zirga a wannan yanki.Ko da yake yana da wahala a tantance dagewar buƙatu, haɓaka farashin da ingantaccen ribar riba yakamata ya kasance mai dorewa "Fowler yayi sharhi.Dangane da kyakkyawan fata nasa, Fuller ya goyi bayan bijimai, yana mainata ƙimar siye da farashin hannun jari na $65.Wannan burin ya bayyana kwarin gwiwarsa ga ikon RDFN na karuwa da kashi 45% a shekara mai zuwa.(Don duba rikodin waƙar Fuller, danna nan.) Lokacin ƙaura zuwa wasu sassa na Wall Street, ra'ayoyin sun fi rarraba.A cikin watanni uku da suka gabata, an ware sayayya 6, rike 5 da sayarwa 1.A cewar Wall Street, RDFN matsakaicin siye ne.Matsakaicin maƙasudin farashin $50 yana nufin 11% sama da haka.(Duba bincike na hannun jari na Redfin akan TipRanks) Vertiv Holdings (VRT) A matsayin ɗaya daga cikin manyan kayan masarufi na duniya, software da masu ba da sabis, Vertiv Holdings ya taimaka wajen haɓaka kasuwancin haɗin gwiwa na tsarin dijital, wanda adadi mai yawa na ba makawa Bayanan suna buƙatar. za a watsa, bincika, sarrafawa da adanawa.Wall Street ya ce ya karu da kashi 71% a bana, kuma ana iya samun karin riba.Ko da farashin hannun jari ya tashi sosai, Wolfe Research Analyst Nigel Coe har yanzu ya yi imanin cewa yanayin haɗari / sakamako yana da kyau.Ya bayyana cewa: "Mun yi imanin cewa Vertiv wani nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i nau'i) wanda zai iya jawo hankalin masu zuba jari daban-daban: matsakaiciyar kamfani mai girma wanda zai iya samar da ci gaban riba mai ban sha'awa a rangwame kuma yana ƙarƙashin alhakin babban jami'in gudanarwa."Idan ya zo ga VRT A kan hanyar haɓaka, manyan kasuwannin ƙarshensa sune cibiyoyin bayanai da sadarwa.Waɗannan wurare sune wuraren da Coe ke tsammanin samun ci gaba a cikin 2020 da 2021, da kuma rashin lahani na dogon lokaci da aka samu ta hanyar ci gaba da haɓaka ƙarfin bayanai da haɓaka 5G.Bugu da kari, kokarin kiyaye tsayayyen farashi ta hanyar inganta ayyuka daban-daban da rage hadaddun kungiya, gudanarwa ya zayyana hanyar fadada riba zuwa maki 500."Wannan rubutun ne wanda shugaban zartarwa David Cote ya samu nasarar tura shi a lokacin da yake aiki a Honeywell, wanda ya tabbatar mana da cewa za a iya tura irin wannan rubutun a Vertiv," in ji Cohen.Yana da kyau a lura cewa VRT ya janye a cikin kwata na biyu na 2020, tare da net bashi kusan dalar Amurka biliyan 2.1 da net bashi / EBITDA kai 4.2 sau.Ko da a babban ƙarshen wannan kewayon, Coe ya yi imanin cewa ma'auni na iya ƙaddamar da sauri.Don haka, ya ɗauka cewa nan da shekarar 2023 rabon bashi/EBITDA ya ninka sau biyu, sannan sauran babban jarin zai kai dalar Amurka biliyan 1."A halin yanzu ba mu tunanin cewa Vertiv wani bayyanannen labarin ƙaddamar da babban jari ne, amma wannan na iya bayyana a cikin lokacin 2022/23 - ba shakka za mu iya ganin ayyukan saye don haɓaka ƙarfinsa a cikin filin rarraba wutar lantarki da Layer DCIM.Sauran zaɓuɓɓukan da za a iya haɗawa sun haɗa da warware garantin kuɗi (a halin yanzu waɗannan suna nunawa a cikin lissafin ƙididdigar rabonmu na diluted) da kuma yadda ake rarraba rabon kuɗi, wanda zai faɗaɗa yuwuwar mallakar hukumomi.Har ila yau, ba za mu iya yin watsi da gaskiyar cewa yawancin kayan aikin lantarki da suka fi girma Girman dabarun haɗin gwiwar da mahalarta kasuwar suka kafa, waɗannan mahalarta ba su da mahimmanci a cikin cibiyar bayanai. "Duk abin da VRT ya yi ya rinjayi Coe ya sake nanata ƙimarsa mafi girma.Yayin kiran zaɓukan, ya saita farashin farashi na $23, yana nuna yuwuwar 22% na sama.(Don duba rikodin waƙar Coe, danna nan) Shin wasu manazarta sun yarda?su ne.A cikin watanni uku da suka gabata, 4 kawai ainihin ƙimar “saya” aka buga.Saboda haka, saƙon a bayyane yake: VRT siya ce mai ƙarfi.Ganin cewa matsakaicin farashin da aka yi niyya shine $ 20.75, farashin hannun jari na iya tashi da 10% a shekara mai zuwa.(Dubi nazarin hannun jari na Vertiv Holdings akan TipRanks) Disclaimer: Ra'ayoyin da aka bayyana a cikin wannan labarin na babban manazarci ne kawai.Abubuwan da ke ciki don tunani ne kawai.Kafin yin kowane saka hannun jari, yana da matukar mahimmanci don gudanar da binciken ku.
Microsoft, Apple, Alphabet, Facebook, Amazon, AMD, Caterpillar, Comcast, GE, Ford, Pfixer, Visa, UPS, Exxon Mobil, Twitter da sauran kamfanoni sun ba da rahoton sakamakon kwata na uku.
Wani sabon dandali na rabawa don SMEs na Hong Kong-"HSBC Airport" yana haɗa ku zuwa bayanan kasuwanci daban-daban da abubuwan da suka faru
A cikin makon da ya ƙare 22 ga Oktoba, yawan ribar jinginar gida ya faɗi zuwa rikodi mai rahusa.Ana sa ran COVID-19 da siyasar Amurka za su ci gaba da yin tasiri a wannan makon.
Hannun jari na Trifecta za su gano hannun jari a kowace Laraba, kuma ana iya samun wasu damar saka hannun jari masu ban sha'awa a cikin ɗan gajeren lokaci.Yin amfani da nazarin fasaha na waɗannan sigogin hannun jari, kuma inda ya dace, dangane da sabbin ayyuka da ƙima na TheStreet's Quant Ratings, mun cire sunayen biyar.Kodayake ba za mu yi la'akari da bincike mai mahimmanci ba, muna fatan wannan labarin zai ba masu zuba jari sha'awar hannun jari tare da kyakkyawar farawa don ƙarin aikin gida akan sunan.
Bayan shafe shekaru yana aiki akan iskar gas na Amurka, Chevron yana yin cacar iskar gas a makomarsa a yankin gabas ta tsakiya da ke fama da rikici, kuma kwararrun makamashi sun dade suna taka tsantsan.Matakin da babban jami'in kamfanin Michael Wirth ya dauka na samun goyon bayan faretin cewa yankin gabas ta tsakiya na shiga wani zamani na sulhu, wanda zai sa ya zama zabin da ya dace don hakar iskar gas, saboda ana sa ran ba zai yi tsada ba fiye da arha mai tsafta.Bukatar za ta wuce mai.Sabuwar dabarar ita ce, kamfanin na inganta sabbin ma'amalar iskar gas a Masar, Isra'ila, da Qatar, tare da rage yawan kudaden da ake kashewa kan hakar ma'adinai a Amurka.